(Q44960512)

7 December 2017

Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications (English)

1 reference

7 December 2017

0 references

1 reference

Priscilla Velentgas

1

1 reference

7 December 2017

William West

2

1 reference

7 December 2017

Carolyn C Cannuscio

3

1 reference

7 December 2017

Douglas J Watson

4

1 reference

7 December 2017

Alexander M Walker

5

1 reference

7 December 2017

1 September 2006

1 reference

Pharmacoepidemiology and Drug Safety

7 December 2017

1 reference

7 December 2017

15

1 reference

7 December 2017

9

1 reference

7 December 2017

641-652

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

7 December 2017

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

21 January 2018

1 reference

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

21 January 2018

1 reference

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program

21 January 2018

1 reference

Management of acute coronary syndromes

21 January 2018

1 reference

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 January 2018

1 reference

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records

21 January 2018

1 reference

A modified poisson regression approach to prospective studies with binary data

21 January 2018

1 reference

Quasi-likelihood estimation for relative risk regression models

21 January 2018

1 reference

Estimating the Relative Risk in Cohort Studies and Clinical Trials of Common Outcomes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PDS.1192

1 reference

7 December 2017

1 reference